Abstract:Glecaprevir was identified as a potent hepatitis C virus (HCV) protease inhibitor, and a large-scale synthesis was required to support the late-stage clinical trials and subsequent commercial launch. The large-scale synthetic route to glecaprevir required the development of completely new synthetic approaches to the two key structural features: the 18-membered macrocycle 3 and the difluoromethyl-substituted cyclopropyl amino acid 4. In this first manuscript, we describe the route development for the macrocycle 3; the second manuscript will describe the development of a new synthetic route to the difluoromethyl-substituted cyclopropyl amino acid 4 and the final assembly of glecaprevir. The large-scale synthetic route to the macrocycle employed a unique intramolecular etherification reaction as the key step in the macrocycle synthesis, avoiding the scalability limitations of the ring-closing metathesis (RCM) reaction of the enabling route. The large-scale synthetic route to the macrocycle was successfully used to produce the amount of glecaprevir required to support the late-stage clinical development.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.oprd.0c00244?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.oprd.0c00244</a>.Computational methods: all DFT calculations were performed using Jaguar; NMR spectra for compounds 13, 31, 32, 43, 47, 49, 50, and 59; crystal structure data for compound 3 (<a class="ext-link" href="/doi/suppl/10.1021/acs.oprd.0c00244/suppl_file/op0c00244_si_001.pdf">PDF</a>)Crystallographic data for macrocycle 3p-Xylene solvate (<a class="ext-link" href="/doi/suppl/10.1021/acs.oprd.0c00244/suppl_file/op0c00244_si_002.cif">CIF</a>)Crystallographic data for macrocycle 3 toluene solvate (<a class="ext-link" href="/doi/suppl/10.1021/acs.oprd.0c00244/suppl_file/op0c00244_si_003.cif">CIF</a>)Crystallographic data for macrocycle 3 MeCN solvate (<a class="ext-link" href="/doi/suppl/10.1021/acs.oprd.0c00244/suppl_file/op0c00244_si_004.cif">CIF</a>)This article is cited by 1 publications.

The solution structure of macrocyclic glecaprevir and its conformational adaptation mechanism towards antitumor targets

Elucidation of the Solution Structure of Macrocyclic Paritaprevir and Exploration of Its Antitumor Potential Through Molecular Docking

Development of a Large-Scale Route to Glecaprevir: Synthesis of the Macrocycle via Intramolecular Etherification

Structure-based virtual screening of natural compounds as inhibitors of HCV using molecular docking and molecular dynamics simulation studies

An Insight into the Medicinal Chemistry Perspective of Macrocyclic Derivatives with Antitumor Activity: A Systematic Review

Discovery of Quinoxaline-Based P1–P3 Macrocyclic NS3/4A Protease Inhibitors with Potent Activity against Drug-Resistant Hepatitis C Virus Variants

Design, synthesis and evaluation of heteroaryldihydropyrimidine analogues bearing spiro ring as hepatitis B virus capsid protein inhibitors

Synthesis of compounds based on the active domain of cabotegravir and their application in inhibiting tumor cells activity

Insight into the structural requirements of benzothiadiazine scaffold-based derivatives as hepatitis C virus NS5B polymerase inhibitors using 3D-QSAR, molecular docking and molecular dynamics

Multitasking Pharmacophores Support Cabotegravir-Based Long-Acting HIV Pre-Exposure Prophylaxis (PrEP)

Structural modification of the propyl linker of cjoc42 in combination with sulfonate ester and triazole replacements for enhanced gankyrin binding and anti-proliferative activity

Quantum Mechanical-Based Stability Evaluation of Crystal Structures for HIV-Targeted Drug Cabotegravir.

Structure-Enabled Discovery of Novel Macrocyclic Inhibitors Targeting Glutaminase 1 Allosteric Binding Site

Repurposing of drug molecules from FDA database against Hepatitis C virus E2 protein using ensemble docking approach

Computational Study on the Wealth Conformations of Hepatitis C Virus Envelope Glycoprotein 2 and Role of Its Glycan Coat

Abstract 5784: Structure-based drug design against caPCNA for selective cancer chemotherapy development

Docking-guided rational engineering of a macrolide glycosyltransferase glycodiversifies epothilone B

Design, synthesis and anti-HBV activity study of novel HBV capsid assembly modulators

Exploring the Potential of Cyclic Peptidyl Antitumor Agents Derived from Natural Macrocyclic Peptide Phakellistatin 13

Synergistic inhibition of hepatitis C virus infection by a novel microtubule inhibitor in combination with daclatasvir

Structure optimization, synthesis and bioactivity evaluation of novel BCR-ABL tyrosine kinase inhibitor targeting T315I mutation